ArticleBritish journal of pharmacology2014
Midkine: an emerging target of drug development for treatment of multiple diseases.
Article in British journal of pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Comparison of diagnostic accuracy of Midkine and AFP for detecting hepatocellular carcinoma: a systematic review and meta-analysis.Bioscience reports · 2020Pooled it
- Pooled it
- Genetics of educational resilience after adverse childhood experiences.EBioMedicine · 2026Article
- A single-cell hematopoietic microenvironmental atlas reveals progressive maturation of bone marrow vascular niche.Cell regeneration (London, England) · 2025Article
- Midkine (MDK) in cancer and drug resistance: from inflammation to therapy.Discover oncology · 2025Review
- Analysis of blood proteome in influenza-infected patients reveals new insights into the host response signatures distinguishing mild severe infections.Frontiers in immunology · 2025Article
- GPC2 promotes prostate cancer progression via MDK-mediated activation of PI3K/AKT signaling pathway.Functional & integrative genomics · 2024Article
- Midkine: A Cancer Biomarker Candidate and Innovative Therapeutic Approaches.European journal of breast health · 2024Article
- Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment.Nature communications · 2023Article
- Role of Midkine in Cancer Drug Resistance: Regulators of Its Expression and Its Molecular Targeting.International journal of molecular sciences · 2023Review
- Pleiotrophin Interaction with Synthetic Glycosaminoglycan Mimetics.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Anticancer Effects of New Ceramides Isolated from the Red Sea Red AlgaeMarine drugs · 2022Article
- Diagnostic performance of Midkine ratios in fine-needle aspirates for evaluation of Cytologically indeterminate thyroid nodules.Diagnostic pathology · 2021Article
- Gene networks and transcriptional regulators associated with liver cancer development and progression.BMC medical genomics · 2021Article
- Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.Oncogene · 2020Review
- Midkine-a Is Required for Cell Cycle Progression of Müller Glia during Neuronal Regeneration in the Vertebrate Retina.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2020Article
- New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma.Frontiers in oncology · 2020Review
- Midkine drives cardiac inflammation by promoting neutrophil trafficking and NETosis in myocarditis.The Journal of experimental medicine · 2019Article
- Clinical value of jointly detection pleural fluid Midkine, pleural fluid adenosine deaminase, and pleural fluid carbohydrate antigen 125 in the identification of nonsmall cell lung cancer-associated malignant pleural effusion.Journal of clinical laboratory analysis · 2018Article
- Changes of serum midkine as a dynamic prognostic factor to monitor disease status in papillary thyroid cancer.Medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledMidkine is a multifunctional factor and has anti-apoptotic, migration-promoting, angiogenic, anti-microbial and other activities. Midkine ameliorates ischemic injury in the heart and brain, enhances oocyte maturation, and is involved in neurogenesis. On the other hand, midkine is an important factor in the etiology of various diseases, especially those with inflammatory backgrounds. Furthermore, midkine is overexpressed in most malignant tumors and plays roles in their invasive phenotypes as well as in their resistance to chemotherapeutics. Therefore, midkine itself is expected to be useful for the treatment of brain and heart diseases, while midkine inhibitors are promising for the treatment of malignant tumors, multiple sclerosis, restenosis, renal diseases, hypertension and osteoporosis. Blood levels of midkine are also expected to be helpful as disease markers, especially as cancer markers. LINKED ARTICLES: This article is part of a themed section on Midkine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.